Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADIL NASDAQ:KZR NASDAQ:MAAQ NASDAQ:RVPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$0.35-0.6%$0.40$0.22▼$1.30$7.60M1.083.79 million shs889,369 shsKZRKezar Life Sciences$3.87-2.2%$4.15$3.62▼$9.18$28.29M0.6137,922 shs10,941 shsMAAQMana Capital Acquisition$3.79-0.9%$3.93$5.35▼$10.25$30.79MN/A33,075 shs15,439 shsRVPHReviva Pharmaceuticals$0.43-2.8%$0.45$0.30▼$4.28$29.24M-0.041.65 million shs778,124 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals0.00%+0.43%-11.17%+7.66%-67.59%KZRKezar Life Sciences0.00%-2.95%-0.50%-8.99%-30.70%MAAQMana Capital Acquisition0.00%+2.16%+1.34%-6.65%+1,169.26%RVPHReviva Pharmaceuticals0.00%+0.75%-18.09%-42.03%-63.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$0.35-0.6%$0.40$0.22▼$1.30$7.60M1.083.79 million shs889,369 shsKZRKezar Life Sciences$3.87-2.2%$4.15$3.62▼$9.18$28.29M0.6137,922 shs10,941 shsMAAQMana Capital Acquisition$3.79-0.9%$3.93$5.35▼$10.25$30.79MN/A33,075 shs15,439 shsRVPHReviva Pharmaceuticals$0.43-2.8%$0.45$0.30▼$4.28$29.24M-0.041.65 million shs778,124 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals0.00%+0.43%-11.17%+7.66%-67.59%KZRKezar Life Sciences0.00%-2.95%-0.50%-8.99%-30.70%MAAQMana Capital Acquisition0.00%+2.16%+1.34%-6.65%+1,169.26%RVPHReviva Pharmaceuticals0.00%+0.75%-18.09%-42.03%-63.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial Pharmaceuticals 3.00Buy$8.002,198.85% UpsideKZRKezar Life Sciences 2.33Hold$9.00132.86% UpsideMAAQMana Capital Acquisition 0.00N/AN/AN/ARVPHReviva Pharmaceuticals 3.13Buy$5.501,179.07% UpsideCurrent Analyst Ratings BreakdownLatest ADIL, RVPH, MAAQ, and KZR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025RVPHReviva PharmaceuticalsBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSpeculative Buy$14.00 ➝ $7.008/20/2025ADILAdial PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/18/2025RVPHReviva PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00 ➝ $3.008/18/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/15/2025RVPHReviva PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/15/2025RVPHReviva PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $2.007/16/2025KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral6/27/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$0.64 per shareN/AKZRKezar Life Sciences$7M4.04N/AN/A$16.02 per share0.24MAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$13.20M-$1.05N/AN/AN/AN/A-191.31%-153.59%11/12/2025 (Estimated)KZRKezar Life Sciences-$83.74M-$9.69N/AN/AN/AN/A-63.51%-52.13%11/11/2025 (Estimated)MAAQMana Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ARVPHReviva Pharmaceuticals-$29.92M-$0.65N/AN/AN/AN/AN/A-259.17%11/13/2025 (Estimated)Latest ADIL, RVPH, MAAQ, and KZR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RVPHReviva Pharmaceuticals-$0.15-$0.12+$0.03-$0.12N/AN/A8/13/2025Q2 2025ADILAdial Pharmaceuticals-$0.22-$0.18+$0.04-$0.18N/AN/A8/13/2025Q2 2025KZRKezar Life Sciences-$2.15-$1.87+$0.28-$1.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A5.025.02KZRKezar Life Sciences0.037.297.29MAAQMana Capital AcquisitionN/AN/AN/ARVPHReviva PharmaceuticalsN/A0.900.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%KZRKezar Life Sciences67.90%MAAQMana Capital Acquisition68.44%RVPHReviva Pharmaceuticals63.18%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals4.26%KZRKezar Life Sciences9.30%MAAQMana Capital AcquisitionN/ARVPHReviva Pharmaceuticals27.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals2021.83 million20.90 millionNo DataKZRKezar Life Sciences607.32 million6.64 millionNot OptionableMAAQMana Capital Acquisition18.13 millionN/ANot OptionableRVPHReviva Pharmaceuticals568.00 million49.52 millionOptionableADIL, RVPH, MAAQ, and KZR HeadlinesRecent News About These CompaniesReviva Pharmaceuticals price target lowered to $7 from $14 at Benchmark3 hours ago | msn.comReviva Pharmaceuticals (NASDAQ:RVPH) vs. Ironwood Pharmaceuticals (NASDAQ:IRWD) Critical ReviewSeptember 8, 2025 | americanbankingnews.comRVPH: There May Be A Faster WayAugust 19, 2025 | finance.yahoo.comReviva Pharmaceuticals Advances Schizophrenia TreatmentAugust 18, 2025 | tipranks.comReviva Pharmaceuticals price target lowered to $3 from $7 at Roth CapitalAugust 18, 2025 | msn.comReviva Narrows Loss 23% in Fiscal Q2August 14, 2025 | aol.comAReviva Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 14, 2025 | globenewswire.comReviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comReviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.comJune 29, 2025 | investing.comReviva Dives on Stock OfferingJune 26, 2025 | baystreet.caReviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public OfferingJune 26, 2025 | globenewswire.comReviva Pharmaceuticals stock falls after announcing public offeringJune 25, 2025 | za.investing.comReviva Pharmaceuticals Holdings, Inc. Announces Proposed Public OfferingJune 25, 2025 | globenewswire.comRVPH: Open Label Extension Results & Key Opinion Leader DiscussionJune 5, 2025 | finance.yahoo.comReviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 5, 2025 | globenewswire.comReviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaJune 2, 2025 | globenewswire.comReviva to Participate in Upcoming Investor Conferences in May 2025May 20, 2025 | santelog.comSReviva Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 15, 2025 | globenewswire.comReviva to Participate in the A.G.P. Healthcare Company ShowcaseMay 13, 2025 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)May 4, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADIL, RVPH, MAAQ, and KZR Company DescriptionsAdial Pharmaceuticals NASDAQ:ADIL$0.35 0.00 (-0.57%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Kezar Life Sciences NASDAQ:KZR$3.86 -0.09 (-2.15%) As of 02:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Mana Capital Acquisition NASDAQ:MAAQ$3.79 -0.03 (-0.88%) As of 09/12/2025Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.Reviva Pharmaceuticals NASDAQ:RVPH$0.43 -0.01 (-2.78%) As of 02:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
